echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Health Insurance Catalog Adjustments . . . In accordance with the requirements of the Party and the State should be given priority to the transfer of domestic original research drugs.

    Health Insurance Catalog Adjustments . . . In accordance with the requirements of the Party and the State should be given priority to the transfer of domestic original research drugs.

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Based on the domestic large-cycle, promote the "double cycle", on the domestic original research drugs in the "2020 National Health Insurance Drug Catalog Adjustment Work Programme (draft for comments)" what is new? On August 3rd, the State Health Insurance Administration issued the Work Programme for the Adjustment of the 2020 National Health Insurance Drug Catalog (Draft for Comments), which determines the scope of the new round of medical insurance transfers and transfers.
    drugs to be added to the 2020 drug catalogue should meet the basic conditions of clinical necessity, safety and effectiveity, and reasonable price.
    It is recommended that priority be given to the transfer of domestic raw research drugs in order to ensure people's health and health safety and the needs of the internal circular economy, as well as the use of health insurance funds with a higher cost-effective, in general, the national medical insurance directory should give priority to the entry of China's own production of drugs, especially domestic raw research drugs and first imitation drugs.
    Imported drugs in China's domestic pricing is seriously inflated, do not follow the reasonable market pricing of Australian Biopharmaceutical Co., Ltd. production of infant, child and adult spinal muscular dystrophy special effects drug "Nosinasi sodium injection", the Australian government official website identified the general patient charge is only $41, equivalent to 280 yuan, the drug is currently priced at 697,000 yuan each in China.
    domestic price is 2500 times the foreign price.
    compound antibiotic cephalosporine 3800 yuan / bottle, the same drug resistance, the price is 10 to 20 times the domestic similar original research compound antibiotics.
    of such a large gap between the two countries, and does the entry of these drugs into the Chinese market follow the origin mission of the drugs used to cure patients? Does such a large cost gap mean taking up health-care funds or making it worse for vulnerable patients? China has a large number of pharmaceutical companies with excellent research and development capabilities, a large number of original research and innovation drugs for clinical urgent need.
    suggested that, in general, China's health insurance catalogue should give priority to the research and development of innovative drugs and first imitation drugs in China, in order to encourage Chinese pharmaceutical companies to continue to research and development innovation, Chinese employment and tax revenue to the Chinese government, to ensure the national public health and health security, to ensure the needs of China's domestic circular economy, to ensure that the use of China's health insurance fund has a higher cost-effective.
    is it reasonable for the United States to have a large number of "original research drugs" in the health care fund? Even if China-U.S. relations are put aside for the time being, the source of medicine is to cure patients, and medical insurance drugs should follow the basic principles of clinical necessity, safety and effective, and reasonable price.
    we look at a "clinically necessary" American "original drug."
    China has a wide variety of anti-infected drugs, a wide variety of market size of more than 200 billion yuan, and the whole body anti-bacterial drugs in the hospital market accounted for more than 80% of the whole body with anti-infectant drugs.
    Chart 12015-2018 China's hospital market with different types of distribution of anti-infection drugs and can be described as China's largest antibiotic market "clinically necessary" drugs, is known as the United States enterprises 40 years ago, the old research imported cephalosporine sabatan sodium.
    /but not FDA approved for listing in the United States.
    In 1994, cephalosporine Shubatan by Dalian Pfizer company with the commodity name "Shupu Deep" to introduce domestic supply clinical use, due to its huge annual cost of a large number of product promotion, the variety has occupied the top of the list of antibiotic drugs for many years, some areas from widespread application and even excessive to abuse of the situation.
    2019, the market size of this product ranks second in the cephalosporine antibiotic market, the first in the cephalosporine compound preparation market, china's urban public hospital sales of 5.31 billion yuan.
    note that unilateral cephalosporine has been de-listed in the United States.
    cephalosporine schubatan has not yet been approved by the FDA for listing in the United States due to hemolysed side effects and poor stability.
    common adverse reactions such as cephalosporine Shubatan include allergic reactions, abnormal blood clotting function, double thiolycerine-like reactions, impaired liver and kidney function, abnormal blood sugar, etc.
    as early as 2009, cephalosporine Shubatan was named by the SFDA of China on the list of key monitoring of adverse drug reactions.
    In recent years, reports of abnormal blood clotting function caused by cephalosporine Shubatan have been common, and State Drug Administration Proclamation No. 13 of 2019 calls for revision of the drug instructions containing cephalosporine, increased plate plate plate reduction under adverse reactions, hypocoagulase primary blood disorder, clotting disorder, bleeding content, and the addition of warning items on the risk of clotting disorders and bleeding at the beginning of the precautions.
    "279 cases of spontaneous report analysis of drug-based liver injury": 2838 cases of liver injury report, the top 5 varieties of drug-based liver injury drugs are atvastatin, moxisa star, lifopin, Loxyfluoxastar, cephalosporine shubatan.
    has been documented as having a 30% rate of adverse reactions to cephalosporine shubatan.
    , there were clinical reports of severe bleeding deaths caused by severe clotting abnormalities caused by cephalosporine shubatan.
    In addition, we are concerned that Chapter 25 of the authoritative original English-language book KUCERS's USE OF ANTIBIOTICS (SIXTH EDITION)" (Antimicrobial Use, 6th Edition) answers this question with clinical trial results, and cephalosporine cannot be used in the treatment of bacterial meningitis.
    even so, domestic cephalosporine or cephalosporine schubatan instructions are indicated to be available for meningitis treatment.
    To quote SIFIC infection officer micro "to cephalosporine / Mr. Shubatan's open letter: it is good to know you, recognize you really difficult" on a sentence to sum up: Dear cephalosporine / Shubatan, you are from overseas, why prefer me to China, do the people of Capitalist countries in Europe and the United States do not need your protection? Why don't they give you a green card? This is not fair to you, should eliminate discrimination against you ah! The draft opinions on the scope of the new drugs to be added are clear, in accordance with Articles 7 and 8 of the Interim Measures for the Administration of Drug Use in Basic Medical Insurance, and medicines that are outside the drug catalogue in one of the following circumstances may be included in the proposed new drug scope in the 2020 National Basic Medical Insurance Drug Catalog (hereinafter referred to as the Drug Catalog).
    1. Medication for the treatment of respiratory diseases associated with neo-crown pneumonia.
    2. Medicines included in the National Essential Medicines Directory (2018 edition).
    3. To be included in the list of new drugs in urgent need of overseas medicines in clinical practice, to encourage generic drugs or to encourage research and development to declare the list of children's drugs, and to be approved for market by the State Drug Administration by December 31, 2019.
    4. The second batch of national organizations focused on the procurement of selected medicines.
    between 1 January 2015 and 31 December 2019, drugs (including new active ingredients and new dosage forms) approved for listing by the State Drug Administration in accordance with the application process for the registration of new drugs.
    . Between 1 January 2015 and 31 December 2019, drugs with significant changes in adaptive disorders, functional treatments, etc. were applied for and approved by the National Drug Administration on the basis of clinical trial results.
    . By December 31, 2019, enter the latest version of the list of medical insurance drugs at or above the provincial level.
    , the main active ingredients are included in the "first batch of national key monitoring of rational drug use drug catalog" except.
    of the New Crown, the treatment of respiratory diseases associated with neo-crown pneumonia is included in the proposed new scope.
    in this new crown outbreak, domestic pharmaceutical enterprises have been actively donating medicine materials for the anti-epidemic work.
    donated drugs for domestic enterprises independently developed class I new drugs.
    , especially since 2009, Chinese regulators have given positive signals about innovative drugs, with more innovative drugs and generics on the market.
    China's State Drug Administration (NMPA, formerly CFDA) has made more positive attempts to speed up the review and approval, and promote the development of domestic innovative pharmaceutical enterprises as well as traditional pharmaceutical enterprises innovation input and transformation.
    On the same conditions, China's medical insurance catalogue should give priority to the entry of China's original research innovative drugs, domestic I. class (including 1.1 to 1.6 categories) innovative drugs and first imitation drugs, but also should be supported, priority should be included in the new national health insurance catalog.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.